Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
TERN
$41.6689
$
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Next Earnings
2026-02-25
Beta
-0.285
Average Volume
Market Cap
Last Dividend
CIK
0001831363
ISIN
US8808811074
CUSIP
880881107
CEO
Amy L. Burroughs
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
59
IPO Date
2021-02-05
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing | ORBIMED Advisors LLC reduced stake by 5,409,671 shares in Terns Pharmaceuticals; the estimated trade size is $125.01 million based on quarterly average price Quarter-end position value decreased by $30.20 million, reflecting both trading and share price movement Transaction represented 2.55% of fund's 13F reportable AUM Post-trade position: 2,153,300 shares, valued at $86.99 million Stake now makes up 1.78% of fund AUM, placing it outside the fund's top five holdings These 10 Stocks Could Mint the Next Wave of Millionaires › | The Motley Fool | 2026-02-20 00:02:22 |
| Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of “Moderate Buy” by Brokerages | Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has issued a strong buy rating | Defense World | 2026-02-19 01:56:48 |
| Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge | First Turn Management acquired 872,049 shares in Terns Pharmaceuticals during the fourth quarter. The quarter-end Terns Pharmaceuticals position value increased by $35.23 million, reflecting both the new stake and stock price movements. | The Motley Fool | 2026-02-17 12:32:00 |
| Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High? | The consensus price target hints at a 50.9% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | Zacks Investment Research | 2026-02-04 10:56:21 |
| Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) | FOSTER CITY, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of February 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. | GlobeNewsWire | 2026-02-02 16:05:00 |
| Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-12 21:15:58 |
| Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference | CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to provide runway into 2031 FOSTER CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that management will provide an update on 2026 priorities and program milestones during the Company's presentation at the 44th Annual J.P. | GlobeNewsWire | 2026-01-07 16:05:00 |
| Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) | FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. | GlobeNewsWire | 2026-01-02 16:05:00 |
| Terns CEO Amy Burroughs talks cancer drug trial win | Amy Burroughs, Terns Pharmaceuticals CEO, joins 'Fast Money' to talk its latest cancer drug data | CNBC Television | 2025-12-15 18:31:51 |
| Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are $747.5 million. All of the securities were offered by Terns. | GlobeNewsWire | 2025-12-11 16:05:00 |
| Terns Announces Pricing of Upsized $650 Million Public Offering | FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters' option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 11, 2025, subject to customary closing conditions. All of the securities are being offered by Terns. | GlobeNewsWire | 2025-12-09 23:30:00 |
| Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again | Terns Pharmaceuticals, Inc. stock has surged 770% YTD, driven by strong TERN-701 data in chronic myeloid leukemia, or CML, the latest outstanding data set shared yesterday. TERN-701 demonstrated superior major molecular response rates versus Novartis' Scemblix, with robust safety and efficacy in heavily pre-treated CML patients. Management is prioritizing TERN-701, raising $400M for pivotal studies, with Phase 3 initiation and regulatory milestones as key upcoming catalysts. | Seeking Alpha | 2025-12-09 14:34:46 |
| Terns Announces Proposed Public Offering | FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Terns expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares and pre-funded warrants to be sold in the offering will be offered by Terns. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. | GlobeNewsWire | 2025-12-09 06:12:00 |
| Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript | Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript | Seeking Alpha | 2025-12-08 23:27:18 |
| Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting | 64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses > 320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2025 in Orlando, FL. | GlobeNewsWire | 2025-12-08 14:45:00 |
| Terns Pharmaceuticals (NASDAQ:TERN) Hits New 52-Week High – What’s Next? | Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report)'s share price reached a new 52-week high on Saturday. The stock traded as high as $30.25 and last traded at $29.36, with a volume of 6237699 shares trading hands. The stock had previously closed at $27.13. Analysts Set New Price Targets TERN has been the subject | Defense World | 2025-12-08 01:32:51 |
| Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors | New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable assets under management (AUM). | The Motley Fool | 2025-12-03 09:11:57 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G/A | 2026-02-12 | 2026-02-12 | View Filing |
| SC 13G | 2026-02-12 | 2026-02-12 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-02-02 | 2026-02-02 | View Filing |
| 8-K | 2026-01-22 | 2026-01-22 | View Filing |
| 4 | 2026-01-16 | 2026-01-16 | View Filing |
| 4 | 2026-01-16 | 2026-01-16 | View Filing |
| 4 | 2026-01-16 | 2026-01-16 | View Filing |
| 8-K | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 8-K | 2025-12-11 | 2025-12-11 | View Filing |
| 424B5 | 2025-12-11 | 2025-12-11 | View Filing |
| 424B5 | 2025-12-09 | 2025-12-09 | View Filing |
| S-3ASR | 2025-12-09 | 2025-12-09 | View Filing |
| 8-K | 2025-12-08 | 2025-12-08 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| 4 | 2025-11-05 | 2025-11-05 | View Filing |
| SC 13D/A | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-11-03 | 2025-11-03 | View Filing |
| SC 13G | 2025-10-31 | 2025-10-31 | View Filing |
| 8-K | 2025-10-22 | 2025-10-21 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| SC 13G | 2025-09-16 | 2025-09-16 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-08-05 | 2025-08-05 | View Filing |
| 4 | 2025-07-03 | 2025-07-03 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-25 | 2025-06-25 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 8-K | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| EFFECT | 2025-05-27 | 2025-05-27 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| S-3 | 2025-05-08 | 2025-05-08 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| SC 13G | 2025-05-07 | 2025-05-07 | View Filing |
| ARS | 2025-04-29 | 2025-04-29 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| S-8 | 2025-03-20 | 2025-03-20 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 3 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-24 | 2025-02-24 | View Filing |
| 3 | 2025-02-24 | 2025-02-24 | View Filing |
| 8-K | 2025-02-24 | 2025-02-24 | View Filing |
| 8-K | 2025-02-20 | 2025-02-20 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 3 | 2025-02-11 | 2025-02-11 | View Filing |
| SC 13G/A | 2025-02-11 | 2025-02-11 | View Filing |
| 8-K | 2025-02-06 | 2025-02-06 | View Filing |
| SC 13G/A | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2024-12-16 | 2024-12-16 | View Filing |
| 4 | 2024-12-09 | 2024-12-09 | View Filing |
| 8-K | 2024-12-03 | 2024-12-03 | View Filing |
| 4 | 2024-11-19 | 2024-11-19 | View Filing |
| 3 | 2024-11-19 | 2024-11-19 | View Filing |
| 8-K | 2024-11-18 | 2024-11-18 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-15 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| S-8 | 2024-11-12 | 2024-11-12 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Volume Gap | 13.42% | 1.08 | 39 | 0.48 | 0.24 | 22.05 |
| Swarm Intelligence Strategy | 10.92% | 0.99 | 39 | 0.36 | 0.25 | 19.55 |
| Pivot Points Strategy | 8.60% | 0.99 | 21 | 0.68 | 0.56 | 11.04 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxx |
| xxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxx |
| xxxxxxxxx | xxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | x |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |